Mandrola ' s Top Trials to Look for at AHA 2023 Mandrola ' s Top Trials to Look for at AHA 2023

Semaglutide ’s cardiovascular benefit in SELECT, another sham-PCI trial from the ORBITA investigators, and ARTESiA, which examines anticoagulation in subclinical atrial fibrillation, are the top AHA late-breakers for John Mandrola, MD.theheart.org on Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Commentary Source Type: news